Hereditary Fructose Intolerance (ALDOB): What a 23andMe Carrier Result Really Means, Backed by the First 2024 Clinical Guidelines

Hereditary Fructose Intolerance (ALDOB): What a 23andMe Carrier Result Really Means, Backed by the First 2024 Clinical Guidelines

This article is for educational purposes only. It is not a substitute for advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. For any decisions about testing, treatment, or care, consult a qualified clinician. In emergencies, call 911.

Bottom line: In February 2024, researchers published the first-ever Clinical Practice Guidelines for hereditary fructose intolerance (HFI), a systematic review of 35 studies. Read alongside NIH and StatPearls references, the science is reassuring. A 23andMe carrier line is not a diagnosis. HFI is an autosomal recessive condition, so a carrier is healthy. And when a truly affected person follows a strict fructose-free diet, the guideline reports a favorable long-term outlook.

What you’ll learn:

• Why an inherited “carrier” result on a home test is different from having the disease itself
• What the newly consolidated 2024 evidence says about diagnosing HFI without the old, risky “fructose challenge” test
• The exact absolute-risk numbers for your other children and future pregnancies
• How genetic results affect insurance in the United States and Canada, and where the legal gaps are

Genetic terms can feel frightening at midnight. This guide translates the research into plain English. It follows the decision path a worried family actually walks, from a home-test carrier line to the metabolic clinic door.

1. How HFI Is Inherited: The ALDOB Gene and Aldolase B

Hereditary fructose intolerance is caused by changes in a single gene called ALDOB, which sits on chromosome 9. That gene carries the instructions for an enzyme named aldolase B. Think of an enzyme as a tiny factory worker whose only job is to break down a specific ingredient.

Aldolase B performs the second step of processing fructose, the natural sugar in fruit. It splits a molecule called fructose-1-phosphate into two smaller, usable pieces. When the enzyme is missing or broken, that molecule piles up in liver cells like unprocessed boxes on a factory floor. This buildup blocks the body from making its own glucose. That causes low blood sugar and toxic effects after eating fructose.

HFI follows an autosomal recessive pattern, meaning a child must inherit one non-working ALDOB copy from each parent to be affected. Every person has two copies of the gene. If only one copy is broken, the working copy covers the job, and that person is a healthy carrier. This is the single most important idea for a worried parent to hold onto.

Researchers have catalogued dozens of ALDOB changes, but two dominate in people of European ancestry. Genomic references document the full spectrum of ALDOB changes and note how ancestry can shift the odds. The two leading variants are:

• A149P (also written p.A150P): appeared in roughly half of patients in studied groups.
• A174D (p.A175D): the next most common, and more frequent in some European populations than others.

In one large American study of 268 disease-causing alleles, A149P and A174D accounted for 44% and 9% of them. Screening for the three most common variants confirmed the diagnosis in about three-quarters of patients in cataloged cohorts.

Why do these two variants matter so much for a family with no known history? Genomic reviews suggest A149P and A174D each arose long ago from a single ancestor. They then spread widely through European-ancestry populations by chance over many generations. That is why a home test can flag a carrier line in someone with no known family history. The variant has simply been passed down quietly for centuries.

Here is the arithmetic that answers most families’ fears. When both parents are healthy carriers, each pregnancy carries a fixed set of odds, like flipping two coins:

Outcome per pregnancy	Chance
Affected child (two broken copies)	25% (about 1 in 4)
Healthy carrier child (one broken copy)	50% (about 1 in 2)
Unaffected child (two working copies)	25% (about 1 in 4)

Importantly, these odds reset with every pregnancy. One affected child does not “use up” the risk or protect the next. A genetic counselor can walk you through these numbers for your own family. You can find one through the National Society of Genetic Counselors at NSGC.org.

Section recap: HFI comes from inheriting a broken ALDOB gene from both parents; a single broken copy makes you a healthy carrier, and two carrier parents face a 25% chance of an affected child per pregnancy.

2. How Common Is It, and Does a Carrier Result Mean Sickness?

Numbers calm the mind better than vague warnings, so here are the real ones:

• Affected (the disease itself): NIH estimates about 1 in 20,000 to 30,000 people worldwide. StatPearls gives a range of 1 in 20,000 to 1 in 60,000, with some estimates as high as 1 in 10,000. In plain terms, this is a rare condition.
• Carriers (healthy, one changed copy): NIH’s rare-disease center estimates about 1 in 71. One American study predicted somewhere between 1 in 55 and 1 in 120 people are carriers.

So being flagged as a carrier puts you in a group of millions of healthy people, not a rare and sick minority.

A carrier is healthy. That deserves repeating, because a home-test report can make “carrier” sound like a verdict. The word means only that you carry one changed copy that you could pass to a child. It has nothing to do with whether you feel well. Carrier status matters for reproductive planning, not for your own daily health.

For a person who is affected, the biology has an unusual feature that explains the timing of symptoms. The enzyme is missing from birth, but the trouble only starts when fructose enters the diet. An exclusively breast-fed infant is symptom-free, because breast milk contains no fructose. Symptoms classically begin at weaning, when fruit, juice, or sweetened foods are introduced. That is why a toddler who suddenly vomits and turns sluggish after fruit and juice deserves a prompt medical look.

It also helps to picture the range of what “affected” can look like:

• Stomach upset, feeding difficulty, and a strong aversion to sweets after fructose exposure
• Low blood sugar (hypoglycemia)
• Liver involvement, from a quiet rise in liver enzymes to, rarely, liver failure
• A kidney problem called proximal renal tubular acidosis (a leak in how the kidney handles certain substances)

None of this is a reason to panic at a single symptom. It is a reason to seek a proper evaluation from a clinician who can look at the whole picture.

There is also a quieter side to HFI. Many affected people develop a strong protective dislike of sweets and simply avoid the foods that harm them. Some live for years undiagnosed, which is one reason the true prevalence is hard to pin down. Sometimes a toddler’s symptoms and an adult’s long-standing sweet aversion both appear in one family. That pattern is worth raising with a pediatrician or a genetic counselor rather than self-diagnosing at home.

Section recap: HFI itself is rare (about 1 in 20,000), while healthy carriers are common (roughly 1 in 71); a carrier result signals reproductive relevance only, and true symptoms in affected people begin when fructose enters the diet at weaning.

3. Testing Options: Home Kit Versus Diagnostic Pathway

There are two very different worlds of genetic testing, and confusing them causes needless panic. A DTC test can start a conversation, but only the clinical pathway can confirm a diagnosis. Here is how the two compare:

Feature	Home kit (DTC)	Clinical diagnostic pathway
Example	23andMe carrier report	ALDOB testing at a metabolic clinic
Purpose	Risk of passing a condition to a child; not for diagnosis	Confirms or rules out the disease
Variants checked	A limited, selected set only	Targeted panel or full gene sequencing
Ordered by	The consumer	A clinician, run at a certified lab

Start with what a home kit actually is. In 2015, the FDA granted 23andMe the first authorization to sell carrier-status reports, later expanding to more than 40 conditions. That authorization is explicit on one point. Carrier reports convey the risk of passing a condition to a child and are not intended to diagnose disease. Home kits also read only a limited, selected set of ALDOB variants, so a “no carrier detected” result does not rule out rarer changes.

For a symptomatic child, the real diagnostic route runs through a pediatric or metabolic clinic. There, doctors order molecular genetic testing of the ALDOB gene, either a targeted variant panel or full gene sequencing, run at a certified laboratory. Supportive clues from bloodwork include low blood sugar, elevated liver enzymes, and signs of kidney tubule stress after fructose exposure. Clinical panels are available through laboratories such as Invitae or Color, ordered by a clinician.

One historical test deserves a clear warning. For decades, doctors used an intravenous “fructose tolerance test,” giving fructose and watching the reaction. The 2024 guideline discourages this test because it can trigger dangerous low blood sugar and, rarely, death. The consolidated evidence now favors genetic confirmation instead. This shift is one of the guideline’s most practical contributions.

It also helps to know what HFI testing is not. HFI is generally not part of standard U.S. newborn screening panels, so it is usually found clinically rather than caught at birth. That makes recognizing weaning-onset symptoms the real “early detection.” If your child has symptoms, do not wait for a screening program to flag it. Raise it directly with your pediatrician or a genetic counselor at NSGC.org.

Section recap: Home kits are limited carrier screens, not diagnostic tools; a real diagnosis needs ALDOB molecular testing at a clinic, and the old fructose tolerance test is now discouraged as unsafe.

4. Reading Your Results: Affected, Carrier, or Uncertain

A genetic report can return several different answers, and knowing the vocabulary keeps a family grounded. There are three main results a clinic may explain, and each carries a very different meaning:

• Affected diagnosis — two disease-causing ALDOB variants are confirmed, one on each gene copy, with a matching clinical and lab picture. Only a specialist integrating genes plus symptoms can make this call.
• Carrier status — one changed copy; the person is healthy; the finding matters for reproductive planning. A 23andMe carrier line points to one detected variant, not disease. Risk to a child rises only when both partners are carriers.
• Variant of uncertain significance (VUS) — a change whose effect is not yet known. ACMG/AMP standards sort variants into five tiers, from clearly harmful to clearly harmless, with VUS in the middle. A VUS can be reclassified later as evidence accumulates. Think of it as an open case file, not a final answer.

Home kits add a specific trap worth naming. A symptomatic child could have a causative variant that the limited home panel simply did not test for. In that case the report may read “clear” while the child is truly affected. This is exactly why HFI can hide behind subtle adult signs, such as fatty liver, poor growth, dental erosion, or a strong sweet aversion. When a family history and these signs line up, that calls for formal evaluation, not a self-diagnosis from a home report. A genetic counselor can help interpret an ambiguous result; find one at NSGC.org.

Section recap: Results come as an affected diagnosis, healthy carrier status, or an uncertain variant; a home-kit “clear” can miss rare variants, so a specialist must combine genotype and symptoms before anyone concludes anything.

5. Prevention and Management: A Lifelong, Label-Reading Diet

For HFI, the “treatment” is food, and it works remarkably well. The cornerstone of care is a strict, lifelong diet that removes fructose, sucrose, and sorbitol, guided by a metabolic dietitian. Sucrose matters because ordinary table sugar is half fructose. Removing these sugars reverses the acute harm and, when maintained, allows normal growth and a near-normal life, which the 2024 guideline links to a favorable prognosis.

Careful label-reading becomes a daily habit, a little like checking prices before you buy. Common sources of hidden fructose and sorbitol to watch for include:

• Fruit, fruit juice, and honey
• High-fructose corn syrup and many processed or sweetened foods
• Ordinary table sugar (sucrose is half fructose)
• Liquid medications, supplements, and even some intravenous fluids

That last item is a crucial and often-missed hazard. Medicines that contain fructose or sorbitol can harm an affected person during illness. The evidence frames this as a real, avoidable risk during hospital care.

Because fruit is eliminated, an affected person can fall short on certain nutrients. Clinicians commonly add vitamin C and folate supplements to fill that gap. A metabolic dietitian tailors this to the individual. This is one more reason the diet needs professional guidance rather than a do-it-yourself approach.

It also helps to reframe what this diet is not. It is not a temporary “elimination diet” to test for a sensitivity, and it is not a low-sugar preference. It is a lifelong medical necessity, because even a single meaningful fructose exposure can trigger acute harm. The upside is that the approach is well defined and effective when followed. Families do not have to invent it from scratch. The 2024 guideline and a metabolic dietitian provide a clear plan they can follow together.

There is a practical safety plan every affected family should build. Flag HFI to every clinician and pharmacist, so that fructose- or sorbitol-containing medications and IV fluids are avoided during any illness or hospital stay. A wallet card or a note in the medical record does this job. It turns an invisible risk into a visible, avoidable one.

Since there is no newborn screen, the real “early detection” is prompt recognition of weaning-onset symptoms followed by genetic evaluation. If sweet foods reliably make a young child sick, treat that as a signal to seek care. Your pediatrician can start the referral, and a genetic counselor at NSGC.org can guide the testing conversation.

Section recap: Management is a lifelong, dietitian-guided diet free of fructose, sucrose, and sorbitol, with vigilant label-reading, vitamin C and folate supplements, and a standing safety flag to keep fructose-containing medicines and IV fluids away.

6. The Latest Treatment and Research Landscape

Families understandably scan headlines for a cure, so let this section be direct. As of 2026, there is no gene therapy, enzyme replacement, or disease-modifying drug approved by the FDA or Health Canada specifically for HFI. Management remains dietary. For context, the only HFI-related FDA action to date authorized 23andMe carrier-status reporting in 2015, not any treatment. Any “gene therapy” headline you see is almost certainly about a different condition, and it does not change HFI care today.

What has changed is the strength of the evidence. In February 2024, researchers published the first-ever Clinical Practice Guidelines for the diagnosis and management of HFI. The work was a systematic review that followed PRISMA methodology across PubMed and pulled together 35 studies. It confirmed HFI as an autosomal recessive disorder from loss of aldolase B, affecting about 1 in 20,000 people, with a favorable prognosis on a fructose-free diet.

The guideline’s practical value lies in what it standardized. It set out a clear diagnostic algorithm and, importantly, favored genetic confirmation over the hazardous fructose tolerance test. It also formalized lifelong dietary management and long-term monitoring. In effect, it turned decades of scattered advice into a single reference clinicians can follow.

The guideline is also honest that even a good diet does not fully solve everything. Some patients can still develop chronic complications despite treatment:

• Fatty liver
• A kidney problem called Fanconi syndrome
• Growth deficiency

For this reason the guideline stresses continuity of care as a patient moves from pediatric to adult medicine. Regular monitoring of the liver, kidneys, growth, and bone health is part of long-term management.

Research questions remain open, and honesty about them is part of good science. The true burden of milder and adult-onset forms is underestimated, partly because many affected people live undiagnosed. The full classification of rarer ALDOB variants and VUS is still evolving under ACMG standards. And long-term outcome data under lifelong dietary management is exactly what the 2024 guideline flags as a monitoring priority. For your own situation, a metabolic specialist and a genetic counselor at NSGC.org can explain how current evidence applies.

Section recap: No drug, enzyme, or gene therapy is approved for HFI as of 2026; the real advance is the first 2024 guideline, which standardized safe diagnosis and dietary care while flagging monitoring for liver, kidney, growth, and bone health.

7. What It Means for the Whole Family: Cascade Testing

A diagnosis in one child sends ripples through a family tree. When a child is affected, both parents are automatically carriers, because each supplied one changed copy. That single fact reshapes what relatives may want to consider. It turns a private result into a family matter.

The main tool here is called cascade testing, which means offering targeted testing outward from the diagnosed person. Who to consider, and why:

• Siblings of an affected child — a first priority; each has a 25% chance of being affected and a 50% chance of being a carrier. Identifying an affected sibling early can spare years of undiagnosed harm.
• Aunts, uncles, and their partners — may want carrier testing for their own reproductive planning.
• An affected person’s future children — carriers or affected, depending on whether the other parent is a carrier.

For future pregnancies, a genetic counselor can lay out reproductive options. These may include prenatal diagnosis during a pregnancy and preimplantation genetic testing, known as PGT-M, during fertility treatment. Neither is a decision to rush; both deserve a careful counseling conversation. The counselor’s role is to explain choices, not to push any one path.

It also helps to think one generation forward. An affected person’s own children will be either carriers or affected, depending on whether the other parent is a carrier. If the partner is not a carrier, every child will be a healthy carrier, not affected. Knowing a partner’s carrier status turns uncertainty into clear numbers.

There is a human side to cascade testing worth naming. Reaching out to relatives about a genetic result can feel awkward, and some family members may not want to know. A genetic counselor can help frame that conversation and respect each person’s choice. No one is obligated to test, and the information is shared as an offer, not a demand. The goal is simply to make sure relatives have the chance to plan with full information.

The practical next step is to reach the right professionals. In the United States, families can locate a board-certified genetic counselor through the NSGC “Find a Genetic Counselor” tool at NSGC.org. In Canada, provincial genetics clinics provide the same service. A counselor coordinates who to test and in what order, so the family does not have to navigate it alone.

Section recap: A diagnosis makes both parents obligate carriers, so cascade testing of siblings and relatives (siblings face a 25% affected chance) plus counseling on prenatal and PGT-M options helps the wider family plan; a certified genetic counselor coordinates it.

8. Insurance, Privacy, and the Emotional Weight in the US and Canada

Behind the genetics sit real-world worries about insurance, jobs, and family disclosure. The good news is that laws in both countries offer meaningful protection, though with important limits. Here is where each protection starts and stops:

Protection	United States (GINA, 2008)	Canada (GNDA, 2017)
Health insurance	Protected	Protected
Employment	Protected	Protected
Life / disability / long-term-care insurance	Not covered by GINA	Covered — broader reach
Legal status	Federal law; some states add more	Upheld by Supreme Court, 2020 (5-4)

In the United States, the Genetic Information Nondiscrimination Act, or GINA, passed in 2008, is the central shield. It bars health insurers and employers from using genetic information to discriminate. The Affordable Care Act separately bans exclusions for pre-existing conditions in health coverage. So a carrier result should not cost you your health plan or your job.

There is one gap every family should understand before buying policies. GINA does not cover life insurance, disability insurance, or long-term-care insurance. Some U.S. states have added broader protections that reach these lines, so local rules matter. A useful mental model helps: GINA is strong where it applies, but its walls do not enclose the whole yard. The exposed corners are exactly the policies families often buy when starting a family. This is a practical reason to consider such policies thoughtfully and, when in doubt, to ask a professional before disclosing results.

Canada offers broader federal protection. The Genetic Non-Discrimination Act became law in 2017, and in 2020 the Supreme Court of Canada upheld its key provisions in a 5-4 decision. The Act makes it illegal to require someone to take or disclose a genetic test as a condition of a service or contract, including insurance. That reaches further than U.S. GINA, which is limited to health insurance and employment.

Coverage for ongoing care differs by system, and specialty costs can slip through. In the U.S., specialist care and monitoring are typically covered by ACA or Medicaid plans. In Canada, provincial health plans cover them, though special foods and supplements may not be. Finally, it is normal to feel shaken by a diagnosis scare, and the lifelong diet is a genuine burden at school, daycare, and restaurants. Yet the consistent message from the evidence is steadying: with disciplined dietary management, the long-term prognosis is excellent. A genetic counselor at NSGC.org can help you weigh insurance timing and the emotional side together.

Section recap: U.S. GINA and the ACA protect health insurance and jobs but leave life, disability, and long-term-care insurance exposed, while Canada’s 2017 law (upheld in 2020) protects more broadly; care is largely covered, though the diet is a real daily burden with an excellent overall outlook.

Frequently Asked Questions

1. My 23andMe report flags me as a carrier for HFI — does that mean I have it? No. A carrier line means you carry one changed ALDOB copy, not two, and carriers are healthy. FDA authorization states these reports are not intended to diagnose disease. It matters for family planning, not your own daily health. Discuss it with a genetic counselor at NSGC.org.

2. How did my child get HFI if my partner and I are both healthy? HFI is autosomal recessive, so two healthy carrier parents can have an affected child when the child inherits a changed copy from each. Each pregnancy carries a 25% chance of an affected child. A metabolic specialist can confirm the diagnosis.

3. My toddler vomits and gets sick after fruit and juice — could this be HFI? It is possible, since HFI symptoms classically start at weaning when fructose is introduced. Only ALDOB molecular testing at a clinic can confirm it, alongside supportive bloodwork. Raise it promptly with your pediatrician rather than self-diagnosing.

4. Is there a cure or medicine for HFI? As of 2026, no drug, enzyme replacement, or gene therapy is FDA- or Health Canada-approved for HFI. Care is a lifelong fructose-free diet, which the 2024 guideline links to a favorable prognosis. A metabolic dietitian guides it.

5. Will a genetic result affect my insurance, and should I get a second opinion? In the U.S., GINA protects health insurance and jobs but not life, disability, or long-term-care insurance. Canada’s 2017 law offers broader protection. A second opinion from a metabolic specialist and a genetic counselor at NSGC.org is always reasonable for a serious result.

Summary

A carrier line on a home genetic test is a starting point for a conversation, not a diagnosis. Hereditary fructose intolerance is a rare, autosomal recessive condition in which a missing aldolase B enzyme cannot process fructose. Because it is recessive, a carrier is healthy, and two carrier parents face a 25% chance of an affected child per pregnancy.

The strongest recent evidence is the first-ever 2024 clinical guideline, a systematic review of 35 studies that standardized safe, genetic-based diagnosis and a lifelong fructose-free diet. There is no approved drug, enzyme, or gene therapy as of 2026, but a disciplined diet gives an excellent long-term outlook. Cascade testing helps the wider family, and laws in the U.S. and Canada protect against many, though not all, forms of insurance discrimination. The single best next step is not another home test. It is a conversation with your pediatrician and a board-certified genetic counselor, who can turn these general facts into a plan for your family.

This article is for educational purposes only. It is not a substitute for advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. For any decisions about testing, treatment, or care, consult a qualified clinician. In emergencies, call 911.

References

1. Úbeda, Santander & Luesma (2024). Clinical Practice Guidelines for the Diagnosis and Management of Hereditary Fructose Intolerance. Diseases 12(3):44. https://www.mdpi.com/2079-9721/12/3/44
2. Singh & Preuss. Hereditary Fructose Intolerance. StatPearls (NCBI Bookshelf, NBK559102). https://www.ncbi.nlm.nih.gov/books/NBK559102/
3. NIH MedlinePlus Genetics. Hereditary fructose intolerance. https://medlineplus.gov/genetics/condition/hereditary-fructose-intolerance/
4. NIH MedlinePlus Genetics. ALDOB gene. https://medlineplus.gov/genetics/gene/aldob/
5. NIH GARD (Genetic and Rare Diseases Information Center). Hereditary fructose intolerance. https://rarediseases.info.nih.gov/diseases/6626/hereditary-fructose-intolerance
6. OMIM #229600. Fructose Intolerance, Hereditary; HFI. https://omim.org/entry/229600
7. OMIM *612724. Aldolase B, Fructose-Bisphosphate; ALDOB. https://omim.org/entry/612724
8. Coffee, Yerkes, Ewen, Zee & Tolan (2010). Increased prevalence of mutant null alleles that cause hereditary fructose intolerance in the American population. J Inherit Metab Dis 33(1):33-42. https://pmc.ncbi.nlm.nih.gov/articles/PMC2954661/
9. FDA (2015). De Novo authorization DEN140044 — 23andMe Personal Genome Service Carrier Status reports. https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN140044.pdf
10. Richards et al. (2015). Standards and guidelines for the interpretation of sequence variants (ACMG/AMP). Genetics in Medicine 17(5):405-424. https://www.nature.com/articles/gim201530
11. NORD (National Organization for Rare Disorders). Fructose Intolerance, Hereditary. https://rarediseases.org/rare-diseases/fructose-intolerance-hereditary/
12. NHGRI / genome.gov. Genetic Discrimination and the Genetic Information Nondiscrimination Act (GINA, 2008). https://www.genome.gov/about-genomics/policy-issues/Genetic-Discrimination
13. Supreme Court of Canada (2020). Reference re Genetic Non-Discrimination Act. https://en.wikipedia.org/wiki/Reference_re_Genetic_Non-Discrimination_Act

---

Last updated: 2026-08-15

Author: genelumen editorial team. This article aggregates 13 sources from peer-reviewed medical literature and public health agencies (tier 1=8 / tier 2=5), including NIH MedlinePlus/GARD, OMIM, StatPearls (NCBI), the FDA, ACMG guidelines, NORD, and the Supreme Court of Canada.

This article is for educational purposes only and is not a substitute for medical advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. In emergencies, call 911 (US/Canada) or 119 (Japan).

Related: Metabolic and Hematologic Genetic Diseases

🌐 日本語版: https://genelumen.com/ja/ja-metabolic-hematologic-genetic/hereditary-fructose-intolerance-aldob-inheritance-carrier-guide